Abstract
We present a case of thymic carcinoid, in which primary and metastatic lesions of lymph nodes and bones could be detected by [(18)F]fluoro-2-deoxy-D-glucose (FDG)-PET, but not by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) SPECT, or by (99m)Tc-methylene diphosphonate ((99m)Tc-MDP) bone scintigraphy. FDG-PET may be a useful tool for managing thymic carcinoids in patients with negative results on (123)I-MIBG SPECT or (99m)Tc-MDP imaging.
MeSH terms
-
3-Iodobenzylguanidine
-
Aged
-
Bone Neoplasms / diagnostic imaging*
-
Bone Neoplasms / secondary
-
Carcinoid Tumor / diagnostic imaging*
-
Carcinoid Tumor / pathology
-
Carcinoid Tumor / therapy
-
Fluorodeoxyglucose F18
-
Humans
-
Iodine Radioisotopes
-
Lymphatic Metastasis
-
Male
-
Positron-Emission Tomography*
-
Radiopharmaceuticals
-
Technetium Tc 99m Medronate
-
Thymus Neoplasms / diagnostic imaging*
-
Thymus Neoplasms / pathology
-
Thymus Neoplasms / therapy
Substances
-
Iodine Radioisotopes
-
Radiopharmaceuticals
-
Fluorodeoxyglucose F18
-
3-Iodobenzylguanidine
-
Technetium Tc 99m Medronate